StreetInsider.com News Articles

Premarket movers: Brazilian ADRs surge, Leslie’s plunges

Mon, 05 Oct 2026 07:25:25 -0400

Invezing.com - U.S. stock futures pointed lower on Monday, signaling a cautious start to the trading week as investors kept tabs on bond-market jitters and the outlook for Federal Reserve interest rates.

By 06:08 ET (10:08 GMT), the Dow futures contract had fallen 92 points, or 0.2%, S&P 500 futures had dropped 13 points, or 0.2%, and Nasdaq 100 futures had dipped 69 points, or 0.2%.

Here are some of the biggest premarket U.S. stock movers today:

Shares of Group 1 Automotive fell 2.1% after Morgan Stanley downgraded the stock to Underweight from Equalweight and cut its price target to $232 from $300.

Analyst

Premarket movers: Brazilian ADRs surge, Leslie’s plunges

Mon, 05 Oct 2026 07:25:25 -0400

By 06:08 ET (10:08 GMT), the Dow futures contract had fallen 92 points, or 0.2%, S&P 500 futures had dropped 13 points, or 0.2%, and Nasdaq 100 futures had dipped 69 points, or 0.2%.

Here are some of the biggest premarket U.S. stock movers today:

Shares of Group 1 Automotive fell 2.1% after Morgan Stanley downgraded the stock to Underweight from Equalweight and cut its price target to $232 from $300.

Analyst

Premarket movers: Brazilian ADRs surge, Leslie’s plunges

Mon, 05 Oct 2026 07:25:25 -0400

By 06:08 ET (10:08 GMT), the Dow futures contract had fallen 92 points, or 0.2%, S&P 500 futures had dropped 13 points, or 0.2%, and Nasdaq 100 futures had dipped 69 points, or 0.2%.

Here are some of the biggest premarket U.S. stock movers today:

Shares of Group 1 Automotive fell 2.1% after Morgan Stanley downgraded the stock to Underweight from Equalweight and cut its price target to $232 from $300.

Analyst

Leerink Assumes Zentalis Pharmaceuticals (ZNTL) at Outperform

Mon, 05 Oct 2026 06:44:29 -0400

Leerink analyst Asthika Goonewardene assumes coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Outperform rating and a price target of $8.00.

For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.

Shares of Zentalis Pharmaceuticals closed at $2.52 yesterday.

Form 4 Zentalis Pharmaceuticals For: Sep 30 Filed by: Bruns Ingmar

Thu, 01 Oct 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20261001/27137252.html

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 01 Oct 2026 17:10:00 -0400

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on October 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 62,000 shares of the Company’s common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 01 Oct 2026 17:10:00 -0400

Wells Fargo Assumes Zentalis Pharmaceuticals (ZNTL) at Equal Weight

Wed, 30 Sep 2026 06:23:27 -0400

Wells Fargo analyst Yanan Zhu assumes coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Equal Weight rating and a price target of $5.00.

For an analyst ratings summary and ratings history on Zentalis Pharmaceuticals click here. For more ratings news on Zentalis Pharmaceuticals click here.

Shares of Zentalis Pharmaceuticals closed at $2.72 yesterday.

William Blair Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

Tue, 15 Sep 2026 16:09:06 -0400

William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Outperform rating.

The analyst comments "We are initiating coverage of Zentalis Pharmaceuticals based on the potential of the WEE1 inhibitor, azenosertib, to deliver a clinically meaningful overall response rate (ORR) in the ongoing DENALI trial, supporting accelerated approval for the treatment of Cyclin E1+ platinum-resistant ovarian cancer (PROC) patients. We believe azenosertib’s improved selectivity for WEE1 addresses key limitations of AstraZeneca’s first-generation WEE1 inhibitor, adavosertib, which inhibited WEE1 and the related kinase PLK1 with comparable potency, contributing to tolerability issues and its ultimate discontinuation. Azenosertib’s greater kinase

William Blair Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

Tue, 15 Sep 2026 16:09:06 -0400

William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Outperform rating.

Form SCHEDULE 13G/A Zentalis Pharmaceuticals Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260819/26951382.html

Form SCHEDULE 13G/A Zentalis Pharmaceuticals Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:13:00 -0400

si-local-file:///var/storage/secattach/20260819/26951382.html

Form 4 Zentalis Pharmaceuticals For: Aug 14 Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260819/26951380.html

Form 4 Zentalis Pharmaceuticals For: Aug 14 Filed by: WALTERS GROUP

Wed, 19 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260819/26951380.html

Zentalis closes $92.6M public offering of common stock

Mon, 17 Aug 2026 16:01:14 -0400

Zentalis Pharmaceuticals (Nasdaq: ZNTL) closed an underwritten public offering of 26,450,000 shares of common stock at $3.50 per share, generating approximately $92.6 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses, according to a press release.